Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
News is forthcoming. Sell now, regret later if this works out the way I think it will.
Those responsible for unlocking the chill are buying up the float for cheap.
ARQL 71.12M shares, float 42.79M shares
First Eagle raises stake in ARQL to 16.66%, filed 2/6/17
Vanguard files 13G raising stake in NVAX to 7.64%
$ARQL HHMMM
has met resistance at 1.47 last two times. I think it wants to breakout.
Not sure if today's action is related to the maternal RSV phase III trials but, Imagine the implications for NVAX if every pregnant woman in THE WORLD were routinely given the NVAX RSV vaccine to protect their children. That is what would happen if this phase III trial is a success.
also news on ARQ 531. Also institutional activity-1 sell several buys. IMO ARQL is a strong buy. Phase III results from liver cancer treatment will be released in March 2017. Pfizer bought 4.4% of ARQL shares earlier this year.
Posted by Hossein Forouzandeh on Nov 28th, 2016 // No Comments
ArQule logoAlgert Global LLC lowered its position in ArQule Inc. (NASDAQ:ARQL) by 10.9% during the third quarter, Holdings Channel reports. The institutional investor owned 121,292 shares of the company’s stock after selling 14,788 shares during the period. Algert Global LLC owned about 0.17% of ArQule worth $217,000 at the end of the most recent reporting period.
Several other hedge funds also recently bought and sold shares of the company. Bridgeway Capital Management Inc. increased its stake in ArQule by 1.8% in the second quarter. Bridgeway Capital Management Inc. now owns 360,193 shares of the company’s stock worth $684,000 after buying an additional 6,200 shares in the last quarter. BlackRock Fund Advisors increased its stake in ArQule by 11.3% in the second quarter. BlackRock Fund Advisors now owns 162,541 shares of the company’s stock worth $309,000 after buying an additional 16,467 shares in the last quarter. Vanguard Group Inc. increased its stake in ArQule by 10.6% in the second quarter. Vanguard Group Inc. now owns 2,960,487 shares of the company’s stock worth $5,625,000 after buying an additional 282,734 shares in the last quarter. Bank of New York Mellon Corp increased its stake in ArQule by 2.5% in the second quarter. Bank of New York Mellon Corp now owns 87,710 shares of the company’s stock worth $167,000 after buying an additional 2,160 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its stake in ArQule by 5.3% in the first quarter. Jacobs Levy Equity Management Inc. now owns 277,729 shares of the company’s stock worth $444,000 after buying an additional 13,979 shares in the last quarter. 58.10% of the stock is owned by institutional investors.
Is reverse merger still on or acquisition or both?
http://www.msn.com/en-us/money/news/smoke-rising-as-more-states-legalize-marijuana-investing-opportunity-grows/ar-AAl3n2i
Smoke Rising: As More States Legalize, Marijuana Investing Opportunity Grows
2 hrs ago
Where there’s smoke, there’s usually fire.
The nation’s $5.7 billion marijuana industry, almost as large as the sugar-powered holiday, Halloween, is heating up after a string of legalization victories at the ballot box last week.Voters in four states, including California, the nation’s most populous state, and the world’s sixth-largest economy, approved recreational marijuana. Another four states either removed or rolled back barriers to using pot for medicinal purposes. Analysts now expect the weed business to grow to a $50 billion industry within a decade, which is as “bigly” as the current Wall Street darling Big Data. It’s high times for the herb.
Or is it? The surprise presidential victory of Donald Trump has cast some uncertainty into the equation. His nominee for Attorney General, or the nation’s “top cop,” Alabama Republican Jeff Sessions, can charitably be described as less than enthusiastic about marijuana. Sessions has said, “…this drug is dangerous, you cannot play with it, it is not funny, it’s not something to laugh about… Good people don’t smoke marijuana.” So far, investors are betting the political smoke will clear and Sessions – if confirmed by the senate – will states have their way.
Blue Chips, Green Rush
Microsoft Corporation (NASDAQ: MSFT) believes in the future of marijuana. The blue chip behemoth began selling software to government officials for tracking sales earlier this year. Oracle Corporation (NYSE: ORCL) also has a deal cooking to help the New York Department of Health monitor medical marijuana use. But it’s not just Silicon Valley mainstays that are getting involved. A marijuana-focused private equity firm, Privateer Holdings, received attention last year when the Seattle-based company announced that its investors – in a $75 million round of fundraising – included PayPal co-founder and Facebook board member, Peter Thiel. Even suburban gardeners want a piece of the action. Scotts Miracle-Gro Co (NYSE: SMG), the Marysville, Ohio-based company better known for its contributions to your father’s lawn fixation than stoner culture, is joining the rush. The company will have invested more than $400 million in hydroponic equipment by the end of the year, and its chief executive is hoping Scotts will eventually develop branded pesticides designed for use on marijuana plants.
Meanwhile, Big Pharma is testing a series of marijuana-based compounds that investors hope will be the next blockbuster drug. Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a San Diego-based biotech firm, is developing a cannabis-based painkiller known as APD371 that’s being billed as a possible alternative to painkilling opiates that have high rates of addiction and abuse. Another big player, Insys Therapeutics Inc (NASDAQ: INSY), is testing out a cannabis-based anti-nausea compound. (Interestingly, INSYS donated $500,000 to opponents of an Arizona ballot initiative to legalize recreational marijuana. The Arizona-based company said the measure “fails to protect the safety of Arizona’s citizens, and particularly its children.” The initiative failed.)
Golden State of Mind
Voters in two more large states — Ohio and Texas — may vote next year on marijuana legalization initiatives, as well. But for now, most eyes are on California, which became the first state to approve medical marijuana in 1996. The state’s pot industry could grow to a $6.5 billion behemoth by 2020, according to ArcView Market Research, an Oakland, Calif.-based firm that monitors the legal marijuana market.
While most attention is likely to be focused on companies that grow or use marijuana for new products, investors will also have plenty of opportunities to put their money into less-risky ancillary businesses, such as lighting, security real estate and social media that offer many of the benefits of a growth stock without the risks of a heavy investment into commodities or pharmaceutical development markets.
Investors should also remember that not all pot-related paranoia is groundless; consider Medbox. The West Hollywood, Calif.-based company was created to sell vending machine-like boxes to businesses where medical marijuana could be sold. Its stock, trading around $3 per share in early November 2012, skyrocketed to $205 on November 15 after an encouraging mention by Marketwatch.
While the company issued a statement to dampen the enthusiasm, the stock only dropped to $20 per share. It remained in the double-digits for the next two years before sinking into near-oblivion. The company, renamed Notis Global Inc., said earlier this week that its stock has hit a 52-week high of 6 cents.
It’s currently trading at 0.03 cents per share.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
How can I get ARNA added to the cannabis stocks list on "Hot"? Thanks for assistance.
Mods, please add ARNA to the cannabis stocks list. They are working on a pain medication made from cannabis which has promising potential.
http://www.msn.com/en-us/money/news/smoke-rising-as-more-states-legalize-marijuana-investing-opportunity-grows/ar-AAl3n2i
hope you are right. someone posted a while back the pps needed to revisit the 1.18 low and it did today.
Agreed, I am an NVAX believer. Added more today. Any news and I think she doubles. An avian flu epidemic may be brewing now and could send this higher.
I don't understand the selling this low. Leaner company now with enough cash to fund operations for a couple years, working on several different vaccines.
Hoping NVAX is working on H5N8 (recent cases in Netherlands, Germany, Austria, Hungary, Poland, Switzerland, Iran, France, and Egypt) and Zika (case found this week for first time in Texas).
NVAX potential takeover target at this low price.
Not sure, unless it came from the conference call.
H5N8 cases in Europe. Potential for NVAX? It is showing a link to an article on TDAmeritrade, but I can't find it.
ARNA ER after the bell today. Looking for some good numbers and guidance.
ARQL Decent report. Bright future. Cheap price.
hope so anyway, 70M short, needs to cover. good luck to longs.
NVAX Should close in the 1.60-1.70 range today, my guess, vol. pressure will pick up.
Must of found a bottom after retracing all the way back to the low from last month. Could be up from here. Good luck.
SUNEQ Blue skies after resistance at .30
according to ct
Anything at all positive from the analyst meeting on Nov. 9th and NVAX should rock...nj :)
That is possible. Also, I think NVAX is misunderstood and was overly/bigly punished for trail results. Looking forward to updates.
$NVAX working on a global instead of regional seasonal influenza vaccine. Nice article. Big potential from one of the other vaccines in the pipeline.
From yesterday's article:
“Novavax’s and Mitsubishi Tanabe’s novel virus-like particle vaccines are also anticipated to further revitalize an influenza market that is gradually moving towards the eventual development of a universal seasonal influenza vaccine.”
$NVAX is a bargain and looks to be heading higher. Those who bought under $2.00 will make a pile of money.
$SUNEQ gapping up- .247X.249.
http://www.marketwatch.com/story/turning-point-in-green-energy-prompts-iea-to-drastically-raise-5-year-outlook-2016-10-25?siteid=yhoof2
Suneq mention. Green energy outlook increased
Hey Clay, great chart yesterday. SUNEQ broke through resistance. Looks like blue skies now. Thanks!
SUNEQ and running like lineq. Quick run to thirties, consolidate and another leg up.
$SUNEQ Great day. Now 21 on IHUB most read. GLBL and TERP both up also.
$SUNEQ Today's action is more accumulation for the pending mega run. coming soon...
all posts are opinions....
$SUNEQ HMM, Might could happen.